BOZILOS 14mg film-coated tablets medication leaflet

L04AA31 teriflunomide • Antineoplastic and immunomodulating agents | Immunosuppressants | Selective immunosuppressants

Teriflunomide is an immunomodulatory medication used for the treatment of relapsing multiple sclerosis. It works by inhibiting de novo pyrimidine synthesis, thereby reducing the activity of immune cells involved in the inflammatory process.

The medication is taken orally, usually once daily, as directed by a doctor. It is important for patients to follow the prescribed dosage and undergo regular medical check-ups to monitor liver and hematological function.

Patients should be aware of potential side effects, such as nausea, diarrhea, or elevated liver enzymes. It is important to inform the doctor of any unusual symptoms or the use of other medications.

Common side effects include nausea, diarrhea, hair loss, and elevated liver enzymes. In rare cases, severe reactions such as hepatotoxicity or allergic reactions may occur. Patients should be informed of these risks before starting treatment.

General data about BOZILOS 14mg

Substance: teriflunomide

Date of last drug list: 10-04-2026

Commercial code: W69318001

Concentration: 14mg

Pharmaceutical form: film-coated tablets

Quantity: 28

Product type: generic

Price: 1736.89 RON

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: PHARMADOX HEALTHCARE LIMITED - MALTA

Holder: EGIS PARMACEUTICALS PLC - UNGARIA

Number: 14812/2022/01

Shelf life: 30 months

Concentrations available for teriflunomide

14mg, 7mg

Compensation lists for BOZILOS 14mg EGIS

NHP 4.A (C2) - Multiple sclerosis

Price

Copayment

Patient

1736.89 RON

1491.30 RON

245.59 RON